UCB

UCB says it worked with MPIRIQ to explore AI-supported identification and referral of patients with suspected axial spondyloarthritis, and that the teams evaluated a referral pathway that uses AI.

Partners: MPIRIQ

UCB says IB Lab FLAMINGO, an AI platform that was originally a UCB initiative, detects vertebral fractures on routine CT scans and is already validated across European health systems. The article says UCB and ImageBiopsy Lab designed and validated a downstream osteoporosis care pathway for patients the tool identifies.

Partners: ImageBiopsy Lab

UCB and the University of Southampton announced DARC, a three-year effort to build an end-to-end in-silico platform for therapeutic antibody design. UCB's head of UK research says the partnership strengthens UCB's position in AI-enabled antibody design.

Partners: University of Southampton

UCB researchers describe FLuID, a federated-learning method for drug discovery, and say that collaborating pharmaceutical companies have improved predictions of how chemical compounds interact with the human body.

UCB and XtalPi announced a license under which Ailux Biologics grants UCB a non-exclusive license to XtalFold, which the release calls a proprietary AI-based software suite for structural insights in biologics discovery and engineering.

Partners: XtalPi, Ailux Biologics

UCB and Aitia announced an early drug-discovery collaboration to discover and validate targets and drug candidates for Huntington's disease. The release describes Aitia as a leader in Causal AI and digital twins for discovering drugs.

Partners: Aitia

UCB and Microsoft announced a multi-year collaboration combining Microsoft's computational services, cloud and artificial intelligence with UCB's drug discovery and development capabilities. The release says the platform can support UCB's scientists.

Partners: Microsoft

Microsoft says UCB created SKAI, a generative-AI platform, and that SKAI powers a family of AI assistants from medical writing to clinical statistics. On the same page a UCB speaker anticipates Microsoft 365 Copilot active use moving from 50% of employees to 80%.

Partners: Microsoft

UCB says its Statistical Science and Innovation group filed a patent application centred on an improved machine learning method that allows AI to predict an outcome or provide decision guidance, and that this innovation has already been used to inform patient stratification, clinical trial design and precision-medicine approaches in Parkinson's disease and epilepsy.